{"generic":"Tedizolid Phosphate","drugs":["Sivextro","Tedizolid Phosphate"],"mono":{"0":{"id":"930989-s-0","title":"Generic Names","mono":"Tedizolid Phosphate"},"1":{"id":"930989-s-1","title":"Dosing and Indications","sub":[{"id":"930989-s-1-4","title":"Adult Dosing","mono":"<ul><li>usual dose, 200 mg ORALLY\/IV infusion over 1 hour once daily for 6 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Acute:<\/b> missed dose, administer as soon as possible, up to 8 hours before next scheduled dose; if less than 8 hours before next dose, wait until next scheduled dose<\/li><\/ul>"},{"id":"930989-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in patients younger than 18 years "},{"id":"930989-s-1-6","title":"Dose Adjustments","mono":"<b>switching routes from IV to oral:<\/b> no adjustment necessary "},{"id":"930989-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Infection of skin AND\/OR subcutaneous tissue, Acute<br\/>"}]},"3":{"id":"930989-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930989-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930989-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- clostridium difficile-associated diarrhea has been reported, including cases occurring more than 2 months after administration; evaluate and institute appropriate medical management if suspected or confirmed<\/li><li>Hematologic:<\/li><li>-- consider alternative therapies in patients with neutropenia (less than 1000 cells\/mm(3))<\/li><\/ul>"},{"id":"930989-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930989-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930989-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (4%), Nausea (8%), Vomiting (3%)<\/li><li><b>Neurologic:<\/b>Dizziness (2%), Headache (6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Tachycardia (less than 2%)<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile colitis (less than 2%)<\/li><li><b>Hematologic:<\/b>Neutropenia (0.5%)<\/li><li><b>Neurologic:<\/b>Peripheral nerve disease (1.2%)<\/li><li><b>Ophthalmic:<\/b>Disorder of optic nerve (0.3%)<\/li><\/ul>"},"6":{"id":"930989-s-6","title":"Drug Name Info","sub":{"0":{"id":"930989-s-6-17","title":"US Trade Names","mono":"Sivextro<br\/>"},"2":{"id":"930989-s-6-19","title":"Class","mono":"<ul><li>Antibacterial<\/li><li>Oxazolidinone<\/li><\/ul>"},"3":{"id":"930989-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930989-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930989-s-7","title":"Mechanism Of Action","mono":"Tedizolid phosphate is the prodrug of tedizolid, an oxazolidinone antibiotic, which inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome.<br\/>"},"8":{"id":"930989-s-8","title":"Pharmacokinetics","sub":[{"id":"930989-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral, Tedizolid: 3.5 hours<\/li><li>Tmax, IV, Tedizolid: 1.2 hours<\/li><li>Bioavailability, Oral: 91%<\/li><li>Effects of food: no change in AUC<\/li><\/ul>"},{"id":"930989-s-8-24","title":"Distribution","mono":"<ul><li>Tedizolid, Protein binding: 70% to 90%<\/li><li>Tedizolid, Vd: 67 to 80 L<\/li><\/ul>"},{"id":"930989-s-8-25","title":"Metabolism","mono":"Tedizolid: active.<br\/>"},{"id":"930989-s-8-26","title":"Excretion","mono":"<ul><li>Feces: 82% is excreted primarily as inactive conjugate; less than 3% is unchanged tedizolid<\/li><li>Renal: 18% is excreted primarily as inactive conjugate; less than 3% is unchanged tedizolid<\/li><li>Dialyzable: No<\/li><\/ul>"},{"id":"930989-s-8-27","title":"Elimination Half Life","mono":"Tedizolid: 12 hours <br\/>"}]},"9":{"id":"930989-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV use only; do not administer via intra-arterial, IM, intrathecal, intraperitoneal, or subQ<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>vials intended for single use only<\/li><li>only reconstitute vial with 4 mL sterile water for injection; may gently swirl and invert vial to aid reconstitution, but avoid shaking during and after reconstitution<\/li><li>further dilute with 250 mL of NS ONLY; do not dilute with lactated Ringer or Hartmann solution<\/li><li>administer only as IV infusion over 1 hour; do not administer via IV push or bolus<\/li><li>do not mix or infuse simultaneously with other drugs or additives during administration<\/li><li>total storage time from reconstitution of vial to administration should not exceed 24 hours regardless of storage method<\/li><\/ul><\/li><li><b>Oral<\/b><br\/>administer with or without food<br\/><\/li><\/ul>"},"10":{"id":"930989-s-10","title":"Monitoring","mono":"improvement in acute bacterial skin and skin structure infections indicates efficacy<br\/>"},"11":{"id":"930989-s-11","title":"How Supplied","mono":"<b>Sivextro<\/b><br\/><ul><li>Intravenous Powder for Solution: 200 MG<\/li><li>Oral Tablet: 200 MG<\/li><\/ul>"},"13":{"id":"930989-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include nausea, diarrhea, vomiting, headache, and dizziness.<\/li><li>Instruct patient to report severe watery or bloody diarrhea, even occurring 2 months after the last dose.<\/li><li>Advise patient of the importance for completing the entire course of therapy.<\/li><li>Instruct the patient to take the missed dose as soon as possible unless the next scheduled dose is in less than 8 hours. In this case, skip the missed dose and resume with the next scheduled dose.<\/li><\/ul>"}}}